The company is building a first-in-class drug development pipeline being led by VT1021, its dual-modulating compound that blocks the CD47 immune checkpoint and reprograms CD36 mediated activities. VT1021 has been investigated as a single agent in a Phase I/II clinical trial i...
EVALUATING THE PRE-CLINICAL EFFICACY OF VT1021 (A CLINICAL STAGE DRUG CANDIDATE) IN MULTIPLE EXPERIMENTAL MODELS OF INFLAMMATORY BOWEL DISEASEdoi:10.1093/ibd/izae020.006Inflammatory bowel disease (IBD) is characterized symptomatically by chronic inflammation in the colonic tract. Despite the increased ...
The most frequent drug-related adverse events are fatigue (15.8%), nausea (10.5%), and infusion-related reactions (10.5%). Exposure increases proportionally from 0.5 to 8.8 mg/kg. The disease control rate (DCR) is 42.9% with 12 of 28 patients deriving clinical benefit including a partial...
(GBM, #1) has been on VT1021 treatment for >1100 days with no measurable lesion detectable. This patient is currently under single patient IND (Investigational New Drug) (Fig.1b). The overall disease control rate (DCR) for rGBM was 45% (95% CI, 0.24–0.67). Among the 17 evaluable p...
oath. The Holton affidavit states the results of the search of the Sharon premises on May 16-17, 1979. It also sets forth that the seizure of the vehicle was in accordance with advice given by Special Agent Theodore Handoga of the Drug Enforcement Administration. The Butts vehicle was ...
Other drug-related AEs included grade 1-2 fatigue, myalgia and dizziness. Dose proportionality was observed in PK analysis. Evidence of Tsp-1 expression, as measured by IHC on tumor biopsies, was observed. Prolonged stable disease was observed in 2 patients including ovarian and colorectal cancer...